Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab (Lucentis) as adjuvant treatment for rubeosis and neovascular glaucoma
2008-005464-14Phase 2Completed
- Sponsor
- Prof. Salvatore Grisanti
- Start
- Nov 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in Iris neovascularization (NVI) and neovascular glaucoma (NVG), sponsored by Prof. Salvatore Grisanti. Primary endpoint: Change in degree of iris rubeosis. Started Nov 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
Iris neovascularization (NVI)neovascular glaucoma (NVG)
Beyond the preview
Go deeper on 2008-005464-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005464-14.